Mintz advised SightLine Applications, a leading developer of sensor processing software for autonomous and uncrewed systems, backed by Artemis, on its acquisition of Athena AI, an Australia-based specialist in AI-enabled computer vision and decision support for defense applications. 

Mintz advised Searchlight Cyber, a portfolio company of Charlesbank Capital Partners, on the acquisition of Assetnote, an Australian-based Attack Surface Management (ASM) platform provider. 

Mintz advised Artemis, a Boston-based private equity firm focused on partnering with differentiated industrial tech companies, on the acquisition of Richland Glass Company, LLC, an Advanced Materials manufacturer of specialty glass containment products and solutions. 

Mintz advised DW Healthcare Partners (DW) on the organization of a continuation vehicle to extend DW’s investment in its portfolio company, Med Learning Group, a continuing medical education company, and to provide additional capital to support the company’s further development and growth. 

Mintz advised Artemis Capital Partners, a Boston-based private equity firm focused on partnering with differentiated industrial tech companies, on its acquisition of Diamond Antenna and Microwave Corporation, a developer of advanced radio frequency rotary joints and rotating subsystems serving mission critical ground, shipboard, submarine, aircraft, commercial, and space applications.

WASHINGTON, DC – Mintz served as legal counsel to Invited, Inc. in its sale of certain assets related to its BigShots Golf business to Topgolf Callaway Brands Corp.

BOSTON– Mintz represented Gradiant Corporation, a global end-to-end solutions provider of advanced water and wastewater treatment, in its Series D financing.

Mintz's role acting for biotechnology company Albireo Pharma in its sale to Ipsen was covered in The Deal. The article featured Mintz Members Megan Gates, and John Condon and Associate Garrett Galvin, who led for the firm.

Mintz completed a deal as counsel to Med-Pharmex in its sale to British-owned veterinary products developer and manufacturer Dechra Pharmaceuticals. Through the sale, Dechra will gain further access and nearly 40 years of experience in the U.S. veterinary health market. 

Mintz's interdisciplinary team continues its leadership role in life sciences, serving as legal counsel to ProKidney LP in its $2.6 billion SPAC merger, and its subsequent listing on the Nasdaq under the ticker symbol "PROK". ProKidney is a leading clinical-stage cellular therapeutics company focused on chronic kidney disease. ProKidney's lead product candidate is in Phase 3 clinical development and has the potential to slow, stabilize and reverse decline in kidney function

The deal will take public ProKidney, a leading clinical-stage cellular therapeutics company focused on chronic kidney disease, and is expected to provide up to $825 million in gross cash proceeds.